Literature DB >> 3003312

Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations.

J M Nesland, R Holm, J V Johannessen, V E Gould.   

Abstract

Thirty-eight infiltrating ductal carcinomas, nine infiltrating lobular carcinomas, two tubular carcinomas and one papillary carcinoma were studied by light microscopy, immunocytochemistry and electron microscopy. Seventeen cases showed immunoreactivity for NSE. Immunostaining for different peptide-hormones was observed in 12 of these 17 cases and in none of the 10 NSE-negative cases used for controls. Scattered cells were positive for gastrin in five cases, pancreatic polypeptide in five, leu-enkephalin in three, sub-P in two, ACTH in one, bombesin in one and beta-endorphin in one case. Four cases revealed immunoreactivity for more than one peptide-hormone. Typical neuroendocrine granules were seen in five cases (all positively stained for NSE). Small, electron dense granules of possible neuroendocrine nature were not found in any of the 33 NSE-negative tumours. Our results confirm that immunoreactivity for NSE is present in a high proportion of breast carcinomas, but that neuroendocrine differentiation cannot be proved to be present in all these cases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3003312     DOI: 10.1002/path.1711480107

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

1.  Immunoreactive opioid peptides in human breast cancer.

Authors:  L Scopsi; E Balslev; N Brünner; H S Poulsen; J Andersen; F Rank; L I Larsson
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

2.  Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker.

Authors:  A Grauer; F Raue; E Rix; C Tschahargane; R Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Localization of neuron-specific (gamma gamma) enolase in proliferating (supportive and neoplastic) Schwann cells. An immunohisto- and electron-immunocyto-chemical study of ganglioneuroblastoma and schwannomas.

Authors:  S A Vinores; M M Herman; L J Rubinstein
Journal:  Histochem J       Date:  1987-08

4.  Immunocytochemical reactivity of breast cancer tissue with antibodies to neuron-specific enolase and an adenocarcinoma-associated glycolipid antigen.

Authors:  H Ingelman-Sundberg; B Wikström; N Stormy; P Sundelin; A Hjerpe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

5.  The significance of argyrophilia in human breast carcinomas.

Authors:  J McCutcheon; R A Walker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

6.  Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry.

Authors:  V E Gould; B Wiedenmann; I Lee; K Schwechheimer; B Dockhorn-Dworniczak; J A Radosevich; R Moll; W W Franke
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

Review 7.  Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives.

Authors:  Alessandro Inno; Giuseppe Bogina; Monica Turazza; Laura Bortesi; Simona Duranti; Alberto Massocco; Giuseppe Zamboni; Giovanni Carbognin; Filippo Alongi; Matteo Salgarello; Stefania Gori
Journal:  Oncologist       Date:  2015-12-09

Review 8.  Carcinomas of the breast with endocrine differentiation: a review.

Authors:  H M Maluf; F C Koerner
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Immunohistochemistry of retinoblastomas.

Authors:  H Sawa; I Takeshita; M Kuramitsu; M Fukui; H Inomata
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

10.  Immunocytochemical analysis of Ewing's tumors. Patterns of expression of intermediate filaments and desmosomal proteins indicate cell type heterogeneity and pluripotential differentiation.

Authors:  R Moll; I Lee; V E Gould; R Berndt; A Roessner; W W Franke
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.